Navigation Links
QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments

PORTLAND, Ore., June 7, 2012 /PRNewswire/ -- QuantRx® Biomedical Corporation (OTCBB: QTXB) is pleased to announce the completion of several key milestones achieved during 2011 and early 2012. The Company has made significant progress on the development of innovative diagnostic products that utilize its patented PadKit™ collection system and genomic technology platform for the furtherance of women's health and fetal medicine world-wide.

The Company boasts two robust proprietary platform technologies focused on a) retail and over the counter applications of its treated and untreated miniform pads including its InSync™ line of feminine hygiene products and Unique™ line of hemorrhoid treatment products, and b) diagnostic applications utilizing its proprietary PadKit™ technology that enables the routine collection of biologic material for later analysis, testing and diagnosis in a laboratory setting. The Company had demonstrated clinical "proof of concept" for the non-invasive collection of fetal cells from a pregnant woman sufficient in quantity to enable the in utero diagnosis of a variety of genomic and metabolic disorders including Down's syndrome and Tay-Sachs disease as well as numerous other metabolic and genomic disorders and abnormalities. Once fully-developed, the Company's fetal diagnostic platform will offer a simple, safe, repeatable and cost effective solution, which could eliminate the need for existing invasive protocols, such as amniocentesis, that pose significant risk to both mother and fetus.

The Company has established a wholly owned subsidiary, QX Labs, Inc., that contains the assets and intellectual property related to the PadKit™ diagnostics and cell collection technologies.  The Company is currently evaluating a variety of alternatives for its QX Labs subsidiary, which may include a strategic partnership, or a partial or full spin-off of QX Labs to current QuantRx® shareholders.

Additionally, we intend to separately secure financing for our women's health over the counter products business, to fund the commercial launch of our Unique™ and InSync™ products and to explore the potential acquisition of complementary products and companies to broaden our product offerings.

Dr. Shalom Hirschman, Chairman of the Board at QuantRx Biomedical, stated, "The Company's technologies and products offer innovative solutions for both feminine hygiene and fetal diagnostics. Our new QX Labs division enables management to provide each business opportunity with the specific resources, personnel, partners and capital necessary to drive success. Our ground breaking PadKit™ diagnostics technologies have the potential to define new standards of care and dramatically improve patient outcomes across a broad range of disease states including HPV detection, cancer testing, and adult and fetal genomics screening. It is a truly an exciting time to be involved with the Company and we believe separating the two businesses offers the most logical approach for funding the businesses and maximizing shareholder value."

About QuantRx Biomedical, Inc.  
QuantRx Biomedical Corporation (OTCBB: QTXB) is focused on the development and commercialization of genomic products for advanced diagnosis of serious disease and health conditions, and innovative over-the-counter miniform based products ( With synergistic expertise in the discovery of diagnostic platforms leveraging a significant portfolio of intellectual property, QuantRx's mission is to introduce products for use by its medical laboratory, and consumers that deliver more accurate, reliable, and cost-effective diagnoses which result in improved patient care and a reduction in overall healthcare costs.

The QuantRx strategy targets significant market opportunities estimated to be in excess of $5 billion worldwide. The Company's technology portfolio, with more than a dozen patents, patents pending and licensed patents, includes: miniform technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs, and significant opportunities in genomic screening and testing for adult and fetal applications, all of which are designed to address significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, management's current plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including; general economic conditions, the Company's need for additional funds, the early state of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


Michael S. Abrams

Burnham Hill Advisors, LLC






SOURCE QuantRx Biomedical Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bunker Hill Community College Holds Biomedical Careers Graduation Ceremony
2. Fluke Biomedical training center goes global: adds multi-language support
3. Nation Must Invest in Biomedical Research/Health Workforce, AAHC President Tells Congress
4. Minority Biomedical Entrepreneurship Conference
5. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
6. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
7. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
8. Live Press Briefing on Findings of Biomedical Industry CEO Survey
9. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
10. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
11. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Frost & Sullivan ... This program addresses ways companies can innovate and ... --> ... --> ... as well as the disrupting factors altering the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Park Systems , world ... scanning ion conductance microscopy module to Park NX10 that is the only product ... SICM benefits virtually all materials characterization that require measurements in liquid such as ...
(Date:12/1/2015)... December 1, 2015 Dr. Harry Lander , President of ... as Chief Science Officer and recruits five distinguished ... Lander , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global ... and development stages of a new closed system for isolating adipose-derived stem cells. The ... vascular fraction (SVF) of adipose tissue. SVF is a component of the lipoaspirate obtained ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):